Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD101 PET Imaging in Suspected Recurrent Brain Metastases
NCT06777433Phase 2Active, not recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 18F-fluoropivalate in brain metastases, sponsored by Radiopharm Theranostics. Primary endpoint: Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium at 1 week. Started Dec 2024; status: active, not recruiting.
02
Drugs
18F-fluoropivalate
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT06777433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777433.